Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How We Manage Patients with Plasmacytomas.
Fotiou D, Dimopoulos MA, Kastritis E. Fotiou D, et al. Among authors: dimopoulos ma. Curr Hematol Malig Rep. 2018 Jun;13(3):227-235. doi: 10.1007/s11899-018-0452-z. Curr Hematol Malig Rep. 2018. PMID: 29667156 Review.
Prevention and treatment of myeloma bone disease.
Terpos E, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Curr Hematol Malig Rep. 2012 Dec;7(4):249-57. doi: 10.1007/s11899-012-0135-0. Curr Hematol Malig Rep. 2012. PMID: 22941027 Review.
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma.
Gavriatopoulou M, Βoultadaki A, Koutoulidis V, Ntanasis-Stathopoulos I, Bourgioti C, Malandrakis P, Fotiou D, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Kastritis E, Terpos E, Dimopoulos MA, Moulopoulos LA. Gavriatopoulou M, et al. Among authors: dimopoulos ma. Blood Cancer J. 2020 Sep 25;10(9):93. doi: 10.1038/s41408-020-00360-9. Blood Cancer J. 2020. PMID: 32978365 Free PMC article. Clinical Trial.
Management of relapsed and relapsed refractory myeloma.
Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG. Kastritis E, et al. Among authors: dimopoulos ma. Hematol Oncol Clin North Am. 2007 Dec;21(6):1175-215, x. doi: 10.1016/j.hoc.2007.08.014. Hematol Oncol Clin North Am. 2007. PMID: 17996594 Review.
Thalidomide in the treatment of multiple myeloma.
Kastritis E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Best Pract Res Clin Haematol. 2007 Dec;20(4):681-99. doi: 10.1016/j.beha.2007.09.001. Best Pract Res Clin Haematol. 2007. PMID: 18070713 Review.
Targeted therapies in multiple myeloma.
Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Target Oncol. 2009 Jan;4(1):23-36. doi: 10.1007/s11523-008-0102-9. Epub 2009 Jan 17. Target Oncol. 2009. PMID: 19343299 Review.
Treatment of relapsed/refractory multiple myeloma.
Kastritis E, Palumbo A, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Semin Hematol. 2009 Apr;46(2):143-57. doi: 10.1053/j.seminhematol.2009.01.004. Semin Hematol. 2009. PMID: 19389498 Review.
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A. Terpos E, et al. Among authors: dimopoulos ma. Leuk Res. 2010 Mar;34(3):399-402. doi: 10.1016/j.leukres.2009.08.035. Epub 2009 Sep 24. Leuk Res. 2010. PMID: 19781774
1,275 results